.Attributes Medication, Posted online: 30 July 2024 doi:10.1038/ d41591-024-00054-wThe antitoxin-- medicine conjugate (ADC) tisotumab vedotin caused boosted progression-free as well as overall survival, causing FDA commendation as well as a brand new therapy choice for clients.